Genomic Testing and Intermediate Risk Prostate Cancer supported by Myriad Oncology

In this episode of the ACRO Podcast, ACRO Committee Member Dr. Nevine Hanna is joined by radiation oncologist Dr. Christopher Lee to discuss how genomic testing is refining risk stratification for patients with intermediate risk prostate cancer. He shares insights on integrating genomic data with clinical factors to guide decisions around active surveillance, radiation therapy, and determining which patients may benefit from androgen deprivation therapy (ADT) post-radiation. The conversation highlights practical takeaways for clinicians focused on more personalized, evidence based prostate cancer care.This episode of the ACRO Podcast is sponsored by Myriad Oncology.